Private Capital Management Inc. lessened its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 23.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,150 shares of the medical research company’s stock after selling 1,550 shares during the quarter. Amgen comprises 1.1% of Private Capital Management Inc.’s portfolio, making the stock its 19th largest holding. Private Capital Management Inc.’s holdings in Amgen were worth $960,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of the business. TrimTabs Asset Management LLC grew its holdings in shares of Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after purchasing an additional 288 shares in the last quarter. Baker Ellis Asset Management LLC purchased a new position in shares of Amgen during the third quarter worth about $108,000. Jackson Grant Investment Advisers Inc. grew its holdings in shares of Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares in the last quarter. Phocas Financial Corp. purchased a new position in shares of Amgen during the second quarter worth about $110,000. Finally, Omnia Family Wealth LLC grew its holdings in shares of Amgen by 25.3% during the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares in the last quarter. 78.46% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $175.25 on Friday. The firm has a market capitalization of $127,220.00, a P/E ratio of 15.83, a P/E/G ratio of 2.55 and a beta of 1.36. Amgen, Inc. has a 12-month low of $145.62 and a 12-month high of $191.10. The company has a debt-to-equity ratio of 1.05, a current ratio of 6.07 and a quick ratio of 5.72.
Amgen announced that its Board of Directors has authorized a stock buyback plan on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be given a $1.32 dividend. This is an increase from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a yield of 3.01%. Amgen’s payout ratio is presently 41.55%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $176.83, for a total value of $269,665.75. Following the completion of the sale, the executive vice president now owns 56,106 shares in the company, valued at $9,921,223.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders sold a total of 8,575 shares of company stock valued at $1,509,339 in the last 90 days. 0.19% of the stock is currently owned by corporate insiders.
AMGN has been the subject of several recent analyst reports. Oppenheimer reissued a “buy” rating and set a $203.00 price objective on shares of Amgen in a report on Friday, October 6th. Mizuho reissued a “buy” rating and set a $198.00 price objective on shares of Amgen in a report on Friday, October 6th. Cann reissued a “buy” rating and set a $203.00 price objective on shares of Amgen in a report on Friday, October 6th. Bank of America boosted their price objective on Amgen to $210.00 and gave the stock a “buy” rating in a report on Thursday, October 5th. Finally, Jefferies Group reissued a “buy” rating and set a $200.00 price objective on shares of Amgen in a report on Monday, September 25th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Amgen currently has a consensus rating of “Hold” and an average price target of $189.94.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
What are top analysts saying about Amgen? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen and related companies.